IDIAP Jordi Gol (IDIAPJGol)

This sponsor has funded 8 studies across 3 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
18510 Planned Assessment of cardiovascular effects of non-insulin glucose-lowering agents. Major cardiovascular events in new users of non-insulin glucose-lowering... Yes No
19017 Finalised Impact of medication adherence on mortality and cardiovascular morbidity: a population-based retrospective cohort study. IMPACT study Yes No
36180 Planned Opioid drug utilization and comparative safety: a population-based cohort study No No
36689 Finalised Comparative safety study of tramadol and codeine users: a population-based cohort study Yes Yes
37205 Finalised Sociodemographic, clinical and pharmacological characteristics associated with the prognosis of patients with SARS-CoV-2 infection (Características... Yes No
37675 Finalised Assessing exposure to cardiovascular therapy, anxiety depressive syndrome treatment and anti-infectives during pregnancy and breastfeeding (Drug... Yes No
48017 Planned Risks of pharmacological interactions of direct oral anticoagulants: thrombotic and hemorrhagic events leading to hospital admission in Catalonia.... No No
104349 Planned Utilization of antidementia treatments: a large multinational-network population-based study. No No

PAS by Risk Management Plan (RMP) requirement

IDIAP Jordi Gol (IDIAPJGol)

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.